dimenhydrinate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
N-methylated xanthine derivatives 901 523-87-5

Description:

MoleculeDescription

Synonyms:

  • dimenhydrinate
  • andramine
  • chloranautine
  • diamarin
  • diphenhydramine 8-chlorotheophyllinate
  • diphenhydrinate
  • dramamine
  • menhydrinate
  • theohydramine
A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY.
  • Molecular weight: 469.97
  • Formula: C24H28ClN5O3
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 31, 1972 FDA ALRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urine abnormality 366.87 15.29 131 24943 5463 46655525
Lymphocyte count decreased 289.62 15.29 177 24897 25412 46635576
Urine leukocyte esterase positive 247.36 15.29 80 24994 2455 46658533
Red blood cells urine positive 185.94 15.29 65 25009 2542 46658446
Blood urine present 175.92 15.29 99 24975 12183 46648805
White blood cells urine positive 170.98 15.29 69 25005 4031 46656957
Urinary sediment present 159.66 15.29 53 25021 1767 46659221
Crystal urine present 128.01 15.29 41 25033 1218 46659770
Urine ketone body present 124.86 15.29 46 25028 2096 46658892
Urine analysis abnormal 116.74 15.29 53 25021 4137 46656851
Enthesopathy 107.99 15.29 52 25022 4638 46656350
Haemoglobin urine present 103.25 15.29 30 25044 636 46660352
Red cell distribution width increased 96.70 15.29 57 25017 7647 46653341
Death 93.35 15.29 32 25042 335516 46325472
Flushing 90.20 15.29 140 24934 64474 46596514
Blood parathyroid hormone decreased 90.18 15.29 45 25029 4336 46656652
Culture urine positive 88.53 15.29 41 25033 3350 46657638
Tongue disorder 86.98 15.29 52 25022 7158 46653830
Chest discomfort 85.84 15.29 165 24909 90104 46570884
Tenosynovitis 84.99 15.29 52 25022 7463 46653525
Aplastic anaemia 82.19 15.29 50 25024 7103 46653885
Red blood cell sedimentation rate 81.44 15.29 32 25042 1741 46659247
Bacterial test 81.05 15.29 29 25045 1214 46659774
Granuloma skin 78.46 15.29 38 25036 3432 46657556
Panniculitis 76.34 15.29 44 25030 5660 46655328
Bacterial test positive 75.41 15.29 40 25034 4376 46656612
Feeling hot 73.31 15.29 96 24978 37832 46623156
Specific gravity urine decreased 73.24 15.29 21 25053 424 46660564
Lymphocyte percentage decreased 71.60 15.29 33 25041 2666 46658322
Monocyte percentage increased 66.75 15.29 24 25050 1019 46659969
Skin necrosis 66.68 15.29 47 25027 8557 46652431
Rheumatoid nodule 62.42 15.29 46 25028 8974 46652014
Body temperature increased 61.06 15.29 71 25003 24790 46636198
Eosinophil count increased 61.03 15.29 43 25031 7823 46653165
Completed suicide 59.72 15.29 5 25069 145915 46515073
Neutrophil percentage increased 59.47 15.29 29 25045 2658 46658330
Nausea 58.20 15.29 593 24481 686861 45974127
Infusion site pain 55.64 15.29 45 25029 10062 46650926
Mean cell haemoglobin concentration increased 55.44 15.29 17 25057 436 46660552
Gangrene 54.40 15.29 33 25041 4662 46656326
Arterial occlusive disease 53.71 15.29 33 25041 4771 46656217
Monocyte count decreased 51.40 15.29 23 25051 1734 46659254
Haematocrit decreased 50.35 15.29 77 24997 34980 46626008
Ulcer 50.13 15.29 54 25020 17338 46643650
Blood creatinine decreased 49.27 15.29 31 25043 4673 46656315
Red blood cell count decreased 48.76 15.29 73 25001 32550 46628438
Headache 45.39 15.29 423 24651 477929 46183059
Blood thyroid stimulating hormone increased 45.33 15.29 32 25042 5837 46655151
Intestinal pseudo-obstruction 45.15 15.29 16 25058 651 46660337
Eosinophil percentage increased 44.71 15.29 17 25057 846 46660142
Insomnia 43.02 15.29 189 24885 164735 46496253
C-reactive protein abnormal 42.90 15.29 55 25019 21215 46639773
Protein urine present 42.02 15.29 29 25045 5102 46655886
Creatinine urine decreased 41.99 15.29 11 25063 156 46660832
Blood pressure fluctuation 41.10 15.29 65 25009 30383 46630605
Heart rate increased 41.08 15.29 110 24964 74681 46586307
Tendonitis 40.57 15.29 44 25030 14233 46646755
Mean cell haemoglobin decreased 40.40 15.29 23 25051 2889 46658099
Leukocyturia 39.68 15.29 16 25058 932 46660056
Specific gravity urine increased 39.55 15.29 11 25063 198 46660790
Red blood cells urine 39.45 15.29 13 25061 423 46660565
Urine leukocyte esterase 38.91 15.29 10 25064 131 46660857
Neutrophil count increased 38.89 15.29 43 25031 14210 46646778
Arteriovenous fistula occlusion 38.80 15.29 12 25062 317 46660671
Blood thyroid stimulating hormone decreased 38.58 15.29 25 25049 3964 46657024
Alveolitis 38.00 15.29 21 25053 2492 46658496
Blue toe syndrome 37.90 15.29 12 25062 343 46660645
Myelocyte count increased 37.77 15.29 12 25062 347 46660641
Oropharyngeal pain 37.67 15.29 106 24968 74062 46586926
Product dose omission issue 37.49 15.29 22 25052 168498 46492490
Chills 37.34 15.29 125 24949 95907 46565081
Red cell distribution width decreased 37.19 15.29 15 25059 874 46660114
Loss of personal independence in daily activities 36.48 15.29 89 24985 57094 46603894
Acute kidney injury 36.28 15.29 44 25030 235811 46425177
Urticaria 36.13 15.29 142 24932 117750 46543238
Hypercalcaemia 35.68 15.29 50 25024 20996 46639992
Tri-iodothyronine free decreased 33.85 15.29 10 25064 225 46660763
Tachycardia 33.83 15.29 124 24950 99498 46561490
Basal cell carcinoma 33.74 15.29 48 25026 20439 46640549
Blood uric acid decreased 33.14 15.29 12 25062 520 46660468
Nitrite urine present 32.84 15.29 13 25061 721 46660267
Mean cell haemoglobin concentration decreased 32.41 15.29 19 25055 2521 46658467
C-reactive protein increased 31.99 15.29 86 24988 58504 46602484
Crystalluria 31.99 15.29 11 25063 409 46660579
Hyponatraemia 31.13 15.29 8 25066 101324 46559664
Bradycardia 31.00 15.29 92 24982 66206 46594782
Cardiac failure congestive 30.68 15.29 6 25068 91744 46569244
Rash pruritic 30.55 15.29 71 25003 44144 46616844
Injection site pain 30.09 15.29 10 25064 107142 46553846
pH urine increased 30.08 15.29 9 25065 212 46660776
Alanine aminotransferase abnormal 29.89 15.29 18 25056 2509 46658479
Multiple sclerosis relapse 29.50 15.29 68 25006 42057 46618931
Gastric disorder 29.35 15.29 52 25022 26653 46634335
Toxicity to various agents 29.01 15.29 43 25031 211723 46449265
Thyroxine free increased 28.95 15.29 12 25062 750 46660238
Throat irritation 28.88 15.29 54 25020 28847 46632141
Fear of injection 28.35 15.29 21 25053 4126 46656862
Infusion related reaction 27.90 15.29 118 24956 101090 46559898
Myelocyte percentage increased 27.78 15.29 8 25066 164 46660824
Oedema peripheral 27.64 15.29 27 25047 159679 46501309
Thrombocytopenia 27.47 15.29 17 25057 126564 46534424
Thyroid disorder 27.19 15.29 33 25041 12043 46648945
Drug ineffective 26.97 15.29 234 24840 677604 45983384
Monocyte count increased 26.72 15.29 22 25052 5042 46655946
Urine oxalate increased 26.51 15.29 8 25066 194 46660794
Band neutrophil percentage increased 26.21 15.29 8 25066 202 46660786
Body temperature decreased 25.99 15.29 34 25040 13375 46647613
Alanine aminotransferase increased 25.85 15.29 105 24969 88346 46572642
Oesophageal spasm 25.70 15.29 15 25059 1974 46659014
Bulimia nervosa 25.61 15.29 10 25064 535 46660453
Drug eruption 25.35 15.29 43 25031 21286 46639702
Drug interaction 25.22 15.29 44 25030 203050 46457938
Nasopharyngitis 25.17 15.29 155 24919 153843 46507145
Poor venous access 24.30 15.29 26 25048 8282 46652706
Cerebrovascular accident 24.19 15.29 12 25062 101027 46559961
Retinal depigmentation 23.89 15.29 8 25066 274 46660714
Renal failure 23.63 15.29 16 25058 113578 46547410
Band sensation 23.44 15.29 10 25064 672 46660316
Red blood cell count increased 23.40 15.29 15 25059 2335 46658653
White blood cell count decreased 22.97 15.29 120 24954 112111 46548877
Mean cell volume decreased 22.88 15.29 15 25059 2425 46658563
Synovitis 22.41 15.29 78 24996 60997 46599991
Band neutrophil count increased 22.38 15.29 8 25066 334 46660654
Seizure 22.23 15.29 20 25054 123034 46537954
Cardio-respiratory arrest 22.06 15.29 3 25071 59866 46601122
Infusion site extravasation 21.99 15.29 20 25054 5236 46655752
Heart rate decreased 21.98 15.29 51 25023 31672 46629316
Palpitations 21.71 15.29 105 24969 95154 46565834
Electrocardiogram QRS complex abnormal 21.36 15.29 7 25067 224 46660764
Vitamin B12 decreased 21.13 15.29 15 25059 2760 46658228
Psoriasis 20.93 15.29 8 25066 78596 46582392
Dizziness 20.67 15.29 276 24798 340138 46320850
Infusion site discomfort 20.40 15.29 9 25065 656 46660332
Colitis microscopic 20.03 15.29 21 25053 6535 46654453
Endometrial ablation 19.96 15.29 9 25065 691 46660297
Oesophageal pain 19.95 15.29 14 25060 2529 46658459
Lipaemic index score 19.71 15.29 5 25069 62 46660926
Skin papilloma 19.68 15.29 17 25057 4159 46656829
Gestational hypertension 19.60 15.29 13 25061 2142 46658846
Angina pectoris 19.60 15.29 44 25030 26731 46634257
Teratoma benign 19.56 15.29 5 25069 64 46660924
Confusional state 19.51 15.29 35 25039 159857 46501131
Red blood cell sedimentation rate increased 19.50 15.29 40 25034 22849 46638139
Drug abuse 19.48 15.29 5 25069 63403 46597585
Overdose 19.11 15.29 16 25058 101963 46559025
Gingival bleeding 18.76 15.29 27 25047 11612 46649376
Infusion site swelling 18.76 15.29 19 25055 5680 46655308
Psoriatic arthropathy 18.46 15.29 52 25022 36327 46624661
Cardiac failure 18.39 15.29 10 25064 79938 46581050
Creatinine urine increased 18.30 15.29 6 25068 192 46660796
Urinary retention 18.16 15.29 42 25032 26019 46634969
Infusion site scar 18.01 15.29 6 25068 202 46660786
Blood pressure increased 17.94 15.29 123 24951 126543 46534445
Immune thrombocytopenia 17.71 15.29 22 25052 8219 46652769
Renal pain 17.60 15.29 18 25056 5443 46655545
Erythema 17.53 15.29 134 24940 142686 46518302
Disease progression 17.51 15.29 14 25060 91286 46569702
Limbal swelling 17.46 15.29 4 25070 31 46660957
Neuropathy peripheral 17.36 15.29 14 25060 90879 46570109
Large intestinal ulcer haemorrhage 17.16 15.29 5 25069 107 46660881
Osteoarthritis 17.04 15.29 6 25068 62019 46598969
Klebsiella test positive 16.93 15.29 9 25065 988 46660000
Heart sounds 16.86 15.29 6 25068 247 46660741
Immature granulocyte count increased 16.73 15.29 6 25068 253 46660735
Change in seizure presentation 16.44 15.29 6 25068 266 46660722
Haemoglobin decreased 16.39 15.29 122 24952 128827 46532161
Mean cell volume increased 16.37 15.29 13 25061 2831 46658157
Urinary casts 16.16 15.29 7 25067 488 46660500
Skin ulcer 16.08 15.29 46 25028 32412 46628576
Multiple organ dysfunction syndrome 16.03 15.29 4 25070 51706 46609282
Defaecation disorder 15.93 15.29 6 25068 291 46660697
Rhinorrhoea 15.88 15.29 59 25015 47606 46613382
Dysmenorrhoea 15.86 15.29 14 25060 3524 46657464
Vaginal discharge 15.77 15.29 16 25058 4792 46656196
Thyroid stimulating immunoglobulin 15.66 15.29 4 25070 51 46660937
Skin reaction 15.65 15.29 24 25050 10922 46650066
Thirst 15.60 15.29 24 25050 10952 46650036
Productive cough 15.44 15.29 61 25013 50654 46610334
Wrong technique in product usage process 15.41 15.29 5 25069 54417 46606571

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enthesopathy 146.37 19.61 45 6672 2861 29942900
Tenosynovitis 137.94 19.61 45 6672 3470 29942291
C-reactive protein abnormal 113.93 19.61 44 6673 5549 29940212
Tongue disorder 106.18 19.61 39 6678 4283 29941478
Aplastic anaemia 96.66 19.61 39 6678 5517 29940244
Synovitis 93.28 19.61 45 6672 9738 29936023
Erythema 89.43 19.61 98 6619 77353 29868408
Tendonitis 82.82 19.61 39 6678 7997 29937764
Alanine aminotransferase abnormal 80.85 19.61 28 6689 2591 29943170
Loss of personal independence in daily activities 71.85 19.61 50 6667 21485 29924276
Psoriatic arthropathy 58.27 19.61 39 6678 15722 29930039
Aspartate aminotransferase increased 51.27 19.61 67 6650 63355 29882406
Alanine aminotransferase increased 50.28 19.61 72 6645 74204 29871557
Nausea 50.20 19.61 163 6554 296794 29648967
Lymphocyte percentage decreased 48.19 19.61 18 6699 2068 29943693
Platelet transfusion 44.14 19.61 14 6703 984 29944777
Treatment failure 43.65 19.61 46 6671 34633 29911128
Heart rate irregular 42.13 19.61 29 6688 12230 29933531
Urine abnormality 41.94 19.61 15 6702 1524 29944237
Febrile neutropenia 40.73 19.61 80 6637 106613 29839148
Victim of child abuse 40.43 19.61 10 6707 280 29945481
Neutrophil percentage increased 39.14 19.61 15 6702 1849 29943912
Lymphocyte count decreased 36.76 19.61 32 6685 19023 29926738
Congenital skin dimples 35.35 19.61 8 6709 151 29945610
Blood pressure fluctuation 34.99 19.61 30 6687 17473 29928288
Death 29.94 19.61 22 6695 357261 29588500
Drug intolerance 29.29 19.61 43 6674 45248 29900513
C-reactive protein increased 29.17 19.61 42 6675 43431 29902330
Epispadias 28.98 19.61 7 6710 177 29945584
Transfusion 28.86 19.61 19 6698 7442 29938319
pH urine increased 28.82 19.61 6 6711 75 29945686
Drug hypersensitivity 28.09 19.61 53 6664 68466 29877295
Child abuse 27.71 19.61 7 6710 214 29945547
White blood cells urine positive 27.11 19.61 10 6707 1109 29944652
Vomiting 27.06 19.61 109 6608 219709 29726052
Headache 25.36 19.61 94 6623 182212 29763549
Pyloric stenosis 25.06 19.61 8 6709 574 29945187
Urine leukocyte esterase positive 24.80 19.61 7 6710 329 29945432
Contraindicated product administered 23.73 19.61 24 6693 17207 29928554
Red blood cell elliptocytes present 22.58 19.61 5 6712 85 29945676
Foetal exposure during pregnancy 22.39 19.61 34 6683 36837 29908924
Red cell distribution width increased 22.38 19.61 13 6704 4081 29941680
Respiratory depression 21.54 19.61 19 6698 11484 29934277
Specific gravity urine increased 21.45 19.61 5 6712 108 29945653
Band neutrophil percentage increased 21.28 19.61 5 6712 112 29945649
Urine ketone body present 20.99 19.61 8 6709 971 29944790
Peripheral motor neuropathy 20.05 19.61 9 6708 1650 29944111

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:37955 h1-receptor blockers
CHEBI has role CHEBI:50919 antiemetico
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Motion sickness indication 37031009 DOID:2951
Vertigo indication 399153001
Vomiting indication 422400008
Nausea indication 422587007
Prevention of Motion Sickness indication
Prevention of Nausea and Vomiting indication
Ménière's disease off-label use 13445001 DOID:9849
Ocular hypertension contraindication 4210003 DOID:9282
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Low blood pressure contraindication 45007003
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Chronic idiopathic constipation contraindication 82934008
Gout contraindication 90560007 DOID:13189
Liver function tests abnormal contraindication 166603001
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Angle-closure glaucoma contraindication 392291006 DOID:13550
Acute coronary syndrome contraindication 394659003
Disorder of coronary artery contraindication 414024009

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 7.43 DRUG MATRIX CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.31 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.69 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.70 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.96 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.48 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 5.60 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.96 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 6.79 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.02 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.10 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.64 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.75 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 5.82 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 5.79 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.85 DRUG MATRIX

External reference:

IDSource
4018048 VUID
N0000146389 NUI
D00520 KEGG_DRUG
4018048 VANDF
C0012381 UMLSCUI
CHEBI:4604 CHEBI
CHEMBL1200406 ChEMBL_ID
DB00985 DRUGBANK_ID
10660 PUBCHEM_CID
D004111 MESH_DESCRIPTOR_UI
61 INN_ID
JB937PER5C UNII
151666 RXNORM
1568 MMSL
4605 MMSL
6646 MMSL
d00861 MMSL
003371 NDDF
387469006 SNOMEDCT_US
81073007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Wal-Dram HUMAN OTC DRUG LABEL 1 0363-0198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Wal-Dram HUMAN OTC DRUG LABEL 1 0363-0198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Driminate HUMAN OTC DRUG LABEL 1 0904-2051 TABLET 50 mg ORAL OTC monograph final 15 sections
Driminate HUMAN OTC DRUG LABEL 1 0904-2051 TABLET 50 mg ORAL OTC monograph final 15 sections
Dimenhydrinate HUMAN OTC DRUG LABEL 1 0904-6772 TABLET 50 mg ORAL OTC monograph final 16 sections
PhysiciansCare DimenhydrinateMotion Sickness Relief HUMAN OTC DRUG LABEL 1 0924-1006 TABLET, COATED 50 mg ORAL OTC monograph final 16 sections
Dimenhydrinate HUMAN OTC DRUG LABEL 1 0924-1007 TABLET 50 mg ORAL OTC monograph final 17 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 11673-198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 11673-198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 11822-0198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 11822-0198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 15127-262 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 15127-262 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion SicknessRelief HUMAN OTC DRUG LABEL 1 24385-004 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 36800-930 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 36800-930 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 46122-536 TABLET 50 mg ORAL OTC monograph final 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 46122-536 TABLET 50 mg ORAL OTC monograph final 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 49035-981 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 49035-981 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
DIMENHYDRINULLTE HUMAN OTC DRUG LABEL 1 49483-352 TABLET, FILM COATED 50 mg ORAL OTC monograph final 11 sections
Airmit Ace HUMAN OTC DRUG LABEL 1 49873-802 TABLET 25 mg ORAL OTC monograph final 12 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 50804-198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 50804-198 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion SicknessOriginal Formula HUMAN OTC DRUG LABEL 1 50804-630 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 50844-199 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 50844-199 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 55315-630 TABLET 50 mg ORAL OTC MONOGRAPH FINULLL 15 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 59779-198 TABLET 50 mg ORAL OTC monograph final 15 sections
Motion Sickness HUMAN OTC DRUG LABEL 1 59779-198 TABLET 50 mg ORAL OTC monograph final 15 sections